secukinumab sold brand name cosentyx among others human monoclonal antibody used treatment psoriasis ankylosing spondylitis psoriatic binds protein interleukin marketed secukinumab used treat psoriasis ankylosing spondylitis psoriatic given subcutaneous injection sold prefilled syringe autoinjector used home lyophilized powder use hospitals october fda approved intravenous variant secukinumab tested pregnant women animal studies show harm relevant doses us food drug administration advises drug used pregnant women risk fetus justified potential european medicines agency ema advises women become pregnant taking european union secukinumab indicated treatment common greater people experience adverse effects include upper respiratory tract common people experience include oral herpes runny nose injection site reactions common occurring approximately clinical trials rare instances hypersensitivity reactions severe infections cases serious inflammatory bowel disease new exacerbations existing caution used starting secukinumab patients inflammatory bowel disease patients treated secukinumab monitored signs symptoms inflammatory bowel secukinumab inhibits member cytokine family interleukin produced mainly inflammatory helper upregulated serum people psoriasis synovial fluid people psoriatic arthritis promotes inflammation binds receptor expressed various types cells including keratinocytes mostly eliminated taken cells via endocytosis broken inside secukinumab recombinant fully human monoclonal antibody manufactured chinese hamster ovary secukinumab discovered developed novartis using developmental name first publication phase trial published january secukinumab approved united states european union treat adults moderatetosevere plaque first inhibiting drug ever january fda approved treat adults ankylosing spondylitis psoriatic arthritis february label update approved include treatment moderatetosevere scalp immune activation dostarlimab ibalizumab httpsenwikipediaorgwikisecukinumab